Research Triangle Park never received much consideration as a location for GlaxoSmithKline (NYSE: GSK) to put a new global center for vaccine research and development, primarily because RTP never supported much of GSK’s vaccine business.
“We don’t do any vaccines R&D in RTP and we only have a handful of employees here who support vaccines,” according to Melinda Stubbee, GSK director of Global External Communications. “The location was selected because in Rockville (Maryland) we have a state of the art facility that meets our demands for the size and technological capability required for vaccines R&D. It is also in close proximity to Washington, D.C., and our key U.S. stakeholders.”
Image: http://www.bizjournals.com/
